Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 274

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 8
Chunk 274
---
 on the disposition of our ordinary shares or ADSs paid within the United States (and, in certain
cases, outside the United States) to U. S. Investors other than certain exempt recipients, such as corporations. Furthermore, backup withholding
may apply to such amounts if the U. S. Investor fails to (i) provide a correct taxpayer identification number, (ii) report interest and
dividends required to be shown on its U. S. federal income tax return, or (iii) make other appropriate certifications in the required manner.
U. S. Investors who are required to establish their exempt status generally must provide such certification on IRS Form W-9.

Backup withholding is not an additional tax. Amounts withheld as
backup withholding from a payment may be credited against a U. S. Investor’s U. S. federal income tax liability and such U. S. Investor
may obtain a refund of any excess amounts withheld by timely filing the appropriate claim for refund with the IRS and furnishing any required
information in a timely manner.

U. S. Investors should consult their own tax advisors concerning
the tax consequences relating to the purchase, ownership and disposition of the ordinary shares or ADSs.

F. Dividends and Paying Agents

Not applicable.

G. Statement by Experts

Not applicable.

102

H. Documents on Display

We are currently subject to the information and periodic reporting
requirements of the Exchange Act, and file periodic reports and other information with the SEC through its electronic data gathering,
analysis and retrieval (EDGAR) system. Our filings with the SEC are available to the public through the SEC’s website at www. sec. gov.
Our SEC filings are also generally available on the ISA’s website at www. magna. isa. gov. iland the TASE’s website at http://www. maya. tase. co. il.

As a foreign private issuer, we are exempt from the rules under
the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are
exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are
not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently
or as promptly as U. S. companies whose securities are registered under the Exchange Act.

We maintain a corporate website at www. biolinerx. com. Information contained on, or that can